Interleukin 6 (IL-6) is known to play an important role in the biology of the malignant plasma cells in multiple myeloma. In an effort to better understand IL-6 stimulated myeloma cell growth, we have performed gene expression profiling to identify IL-6 early response genes. Using the KAS-6/1 IL-6-dependent human myeloma cell line, IL-6 stimulation dramatically induced expression of monocyte chemoattractant protein-1 (MCP-1) mRNA. To verify this result, we used reverse transcriptase PCR and RNAse protection assays and demonstrated using both assays that MCP-1 is indeed an IL-6 responsive gene in a variety of IL-6-responsive myeloma cell lines. Moreover, we also demonstrated IL-6 stimulated MCP-1 secretion by the myeloma cell lines as well as by fresh patient tumor cells. Lastly, we present evidence that fresh patient tumor cells express mRNA for the MCP-1 receptor, CCR2, as do myeloma cell lines along with a second MCP-1 receptor, CCR11. Although MM cell chemotaxis in response to MCP-1 was only minimal, we were able to demonstrate that MCP-1 stimulated activation of MAPK. Because of the important role that this chemokine plays in both angiogenesis and bone homeostasis, and the ability of MCP-1 to activate myeloma cells, these results suggest a new mechanism by which IL-6 may contribute to disease pathogenesis.
Introduction
Multiple myeloma (MM) is a progressive and typically fatal disease characterized by the accumulation of malignant plasma cells in the bone marrow. The localization of large numbers of tumor cells in this environment has been directly linked with the presence of lytic bone lesions 1 as well as with increased angiogenesis. 2 It is likely that both of these sequelae result from tumor cell disruption of the homeostasis of this environment via cell-cell contact and/or elaboration of cytokines. In this regard, IL-6 is one cytokine that is known to play a pivotal role in this disease because of its ability to influence osteoclast activity, protect tumor cells from programmed cell death, and directly stimulate tumor cell growth.
3 IL-6 has been shown to stimulate myeloma cell growth, while functioning primarily as a differentiation factor for normal B lymphocytes. 4 To better understand tumor cell growth control we have been interested in more completely defining IL-6-responsive genes in myeloma cells. As a consequence of our studies, we describe for the first time that IL-6 is a potent inducer of MCP-1 expression in myeloma cells.
MCP-1 is a member of the CC family of chemokines and its known activities include the recruitment of monocytes, NK cells, and subpopulations of T cells. 5 Chemokines can be broadly subgrouped as homeostatic or inflammatory and MCP-1 is classified within the latter subgroup. MCP-1 is currently known to bind to two different receptors designated as CCR2 and CCR11. 6, 7 There has been increasing interest in the role of chemokines in human disease 8 and in this regard, MCP-1 has been linked with increased angiogenesis 9 and bone resorption, [10] [11] [12] two clinical features often observed in multiple myeloma. Of interest, Nesbit and colleagues 13 recently demonstrated that low-level MCP-1 stimulation of monocytes led to tumor formation in nontumorigenic melanoma cells. Given the interesting biological activities of MCP-1 and our preliminary observation that IL-6 induced MCP-1 mRNA expression by myeloma cells, the goal of the current study was to further explore the expression of MCP-1 in multiple myeloma cells and begin to understand its role in the biology of this disease.
Materials and methods

Cell culture and stimulation
The myeloma cell lines ANBL-6, KAS-6/1, KP-6, DP-6, and DT-6I were derived in our laboratory and are maintained with IL-6 (kindly provided by Novartis Pharma, Basel, Switzerland) as previously described. 4 Normal human B lymphocytes were purified as previously described 4, 14 and were Ͼ95% pure on the basis of cell phenotype. Patient bone marrow-derived tumor cells were purified using CD138 (syndecan-1) microbeads and the Miltenyi magnetic cell sorting system (Miltenyi Biotec, Auburn, CA, USA) as described by Draube et al. 14 The purity of plasma cells isolated in this manner was 95-98% as judged by morphology. Prior to cytokine stimulation, the cell lines were starved of IL-6 by overnight incubation in RPMI 1640 supplemented with 0.5% BSA (Sigma, St Louis, MO, USA) unless otherwise noted. Starved cells were then stimulated with either IL-6 or MCP-1 (PeproTech, Rocky Hill, NJ, USA) in BSA-supplemented media (unless otherwise noted) for varying lengths of time. IL-6 deprivation of up to 72 h does not appreciably increase cell death (unpublished observations).
cDNA array analysis
Poly A+ RNA was isolated from control and IL-6 stimulated KAS-6/1 cells using a Midi Poly A+ kit (Qiagen, Valencia, CA, USA). Atlas human cDNA expression arrays (Array I) were purchased from Clontech (Palo Alto, CA, USA). Radiolabeled cDNA was prepared and incubated with the membranes according to Clontech's suggested protocol. Data were acquired using a Molecular Dynamics STORM Phosphorimager (Sunnyvale, CA, USA).
Messenger RNA analysis
Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using standard methodology. The primer sequences and their predicted sizes are as follows: MCP-1, S-5′-TTCTCAAACTGAAGCTCGCACTCTCGCC-3′, AS-5′-TGT GGAGTGAGTGTTCAAGTCTTCGGAGTT-3′ (348 bp); ␤ 2 -microglobulin (␤ 2 -MG), S-5′-CTCGCGCTACTCTCTCTTTC TGG-3′, AS-5′-GCTTACATGTCTCGATCCCACTTAA-3′ (335 bp); ␤-actin, S-5′-CAAATGCTTCTAGGCGGACTATGAC-3′, AS-5′-CGAAAGCAATGCTATCACCTCCC-3' (388bp); CCR2, S-5′-ATGCTGTCCACATCTCGTTC-3', AS-5'-TCTATCGAT TGTCAGGAGGA-3' (414 bp); CCR11, S-5'-TCTCTGGAA TGCAGTTTCTGG-3', AS-5'-GTTTGCTCATGTTGCAGCTGG-3' (469 bp). PCR products were visualized on 2% agarose gels and staining with ethidium bromide. RNAse protection assays were performed using the RiboQuant system and the hCK-5 chemokine template commercially available from BD PharMingen (San Diego, CA, USA). Data were acquired using a STORM phosphorimager.
MCP-1 ELISA
A human MCP-1 specific ELISA was purchased from Biosource Intl (Camarillo, CA, USA) and R&D (Minneapolis, MN, USA). Assays were performed as indicated by the manufacturer and levels of secreted MCP-1 were calculated from standard curves set up for each assay. Supernatants were always run in duplicate and the variance between the two samples averaged less than 12%.
MAPK activation assay
Cells were starved overnight in RPMI plus 0.5% BSA. Cells (10 × 10 6 ) were stimulated with 100 ng/ml MCP-1 for various lengths of time at 37°C and lysed in cold lysis buffer (20 mM Tris-HCl; 137 mM NaCl; 1 mM MgCl 2; 1 mM CaCl 2; 1% Nonidet P-40; 10% glycerol; 2 mM EDTA; 10 mM Na pyrophosphate; 10 mM NaF; 2 mM Na 3 VO 4; 2 mM PMSF; 8 g/ml leupeptin, aprotinin, pepstatin; and 4 g/ml DTT). Lysates were cleared of insoluble material by centrifugation for 10 min at 14000 r.p.m. Sixty g of protein were denatured with an equal volume of 2× SDS sample buffer (125 mM Tris, pH 6.8; 5% glycerol; 0.02% SDS (wt/vol); 0.02% 2-mercaptoethanol; 10 g/ml bromophenol blue; solution pH 6.6), boiled for 10 min, and electrophoresed on a 10% SDS-PAGE gel. Proteins were transferred to an Immobilon P membrane (Millipore, Bedford, MA, USA). Membranes were blocked in 25 mM TrisCl (pH 7.2), 150 mM NaCl, 0.2% (wt/vol) Tween 20 (TBST) supplemented with 5% milk for 1 h. Following incubation with the designated primary antibody, HRP-linked anti-rabbit IgG secondary antibody was added and immunoreactive proteins were detected using enhanced chemiluminescence detection and autoradiography.
Flow cytometric analysis
For analysis of MCP-1 receptor expression, cells were incubated for 30 min with either 1 g/ml FITC-conjugated ␣-CKR2b (polyclonal) (Santa Cruz, Biotechnology, Santa Cruz, CA, USA), or a FITC-conjugated isotype matched polyclonal goat IgG. Cells were washed extensively before analysis on a FACS
Leukemia
Figure 1
IL-6 induces MCP-1 RNA expression. The KAS-6/1 cell line was stimulated with or without 5 ng/mL IL-6 for 2 h before isolation of RNA. The figure depicts one quadrant of the Clontech human cDNA expression array and the arrows indicate the hybridization signals for MCP-1 in control vs IL-6 stimulated cells.
Vantage (Becton Dickinson, Mountain View, CA, USA). Data were collected and analyzed using WinMDI software.
MCP-1 migration assay
1 × 10 6 cells were placed in upper wells of transwell chambers with an 8-m filter (Corning/Costar, Corning, NY, USA). MCP-1 was added to the bottom fibronectin-coated transwell chambers. Transwell chambers were incubated for 4 h at 37°C, 6% CO 2 . After incubation, inserts were removed and cells in the bottom wells were labeled using 2 g/ml Calcein, AM (Molecular Probes, Eugene, OR, USA) at 37°C for 15 min. Data were collected and analyzed using the Cytofluor multiwell plate reader (Applied Biosystems).
Results
MCP-1 is an IL-6 responsive gene in myeloma cells
As part of our ongoing studies using cDNA array technology to identify IL-6-responsive genes in myeloma cells, we discovered that IL-6 stimulation of the KAS-6/1 myeloma cell line resulted in induction of MCP-1 mRNA expression (Figure 1 ). To verify this result, we first used RT-PCR and we also investigated whether other myeloma cell lines shared this response. As shown in Figure 2 , the KAS-6/1 cell line and three
Figure 2
RT-PCR analysis of MCP-1 mRNA induction. Four myeloma cell lines were stimulated with or without IL-6 for 2 h before isolation of RNA and RT-PCR analysis of MCP-1 and ␤ 2 -MG RNA levels. C designates an oligonucleotide alone control reaction.
additional IL-6-responsive myeloma cell lines were observed to express increased levels of MCP-1 mRNA following IL-6 stimulation. We also used an RNAse protection assay to determine the mRNA expression levels of a variety of chemokines before and after IL-6 stimulation. Figure 3 further supports our conclusion that IL-6 induces myeloma cells to express MCP-1. It is interesting to note that the ANBL-6 and KAS-6/1 cell lines both expressed a variety of other chemokines that did not appear to be regulated by IL-6.
Myeloma cells secrete MCP-1
We next wished to determine if we could detect MCP-1 protein following IL-6 stimulation. First, we tested the ability of varying concentrations of IL-6 to stimulate myeloma cell MCP-1 expression using the KAS-6/1 and DP-6 cell lines (Figure 4 ). Of note, 1 ng/ml IL-6 was sufficient to induce significant MCP-1 expression. IL-6 was used at 5 ng/ml in all subsequent experiments. Second, using the KAS-6/1 cell line, we wished to determine the kinetics of MCP-1 secretion. As can be seen in Figure 5 , MCP-1 secretion was observed as early as 2 h post stimulation. Table 1 To address the possibility that IL-6 deprivation resulted in cell death and that MCP-1 was instead constitutively expressed in myeloma cells, we also analyzed the ability of IL-6 to induce MCP-1 secretion in myeloma cells maintained in FCS or BSA supplemented with insulin-like growth factor-I (IGF-I). As may be seen in Table 1 (experiments 5 and 6), even when cell viability was maintained by FCS or IGF-I during the starvation and/or stimulation periods, IL-6 still induced MCP-1 secretion.
Figure 3
RNAse protection analysis of chemokine expression following IL-6 stimulation. ANBL-6 (AN) and KAS-6/1 (KAS) cell lines were stimulated with or without IL-6 for 3 h prior to RNA isolation. For each lane, 20 g of RNA was incubated with probe overnight before RNAse digestion and separation of protected products on an 8% denaturing acrylamide gel. P designates free probe. L32 is a housekeeping gene and indicates equal starting RNA concentrations between each of the samples.
Figure 4
IL-6 concentration-dependent induction of MCP-1 secretion. DP-6 and KAS-6/1 cells were cultured with the indicated amounts of IL-6 for 24 h before isolation of cell-free supernatants and assessment of MCP-1 by ELISA.
Figure 5
Kinetics of IL-6 induced MCP-1 secretion. KAS-6/1 cells were cultured with or without 5 ng/ml IL-6 and MCP-1 levels were assayed after the indicated lengths of time.
We also examined MCP-1 secretion by freshly isolated CD138 + bone marrow plasma cells from MGUS, Waldenstrom's macroglobulinemia, smoldering myeloma, and multiple myeloma patients. Table 2 indicates the diagnosis and MCP-1 levels. Although the levels of MCP-1 that were secreted were relatively low in comparison with the cell line data, it is interesting to note that we again observed that IL-6 was able to stimulate increased levels of MCP-1 expression, particularly in those patients with MM. Of interest, several of the patient tumor cell specimens secreted MCP-1 in the apparent absence of IL-6 stimulation. It should be noted, however, that these cells were immediately placed in culture following isolation. It is possible, therefore, that these cells had been previously maximally stimulated by IL-6 in vivo. It is also interesting to note the relatively high levels of MCP-1 secretion by cells obtained from one of the patients with smoldering myeloma (115 pg/ml MCP-1 secretion ± IL-6 stimulation). This particular patient has since progressed to active myeloma requiring a bone marrow transplant. The clinical status of the other SMM patient, who expressed enhanced MCP-1 upon IL-6 stimulation, however, has not changed. /ml) were cultured with or without 5 ng/ml IL-6 for the indicated periods of time before harvesting cell-free supernatants and determination of MCP-1 levels by ELISA. Culture conditions: experiments 1-4, cells were starved and stimulated with IL-6 in BSA-supplemented media; experiment 5, cells were starved in BSA supplemented with IGF-I and stimulated with IL-6 in FCS-supplemented media; experiment 6, cells were starved in BSA supplemented media, and stimulated with IL-6 in FCSsupplemented media. /ml) were cultured with or without IL-6 for 24 h before harvesting cell-free supernatants and determination of MCP-1 levels by ELISA. MGUS, monoclonal gammopathy of undertermined significance; WM, Waldenstrom's macroglobulinemia; SMM, smoldering myeloma; MM, multiple myeloma.
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Figure 6
Myeloma cells express mRNA for CCR2. RT-PCR was used to assess CCR2 mRNA expression in each of four myeloma cell lines (a) or primary myeloma cells (b).
MCP-1 receptor expression and function
MCP-1 is known to bind to CCR2 6 and more recently to CCR11. 7 To assess receptor expression on myeloma cells, we next used RT-PCR to measure mRNA for CCR2 in the panel of myeloma cell lines and in fresh patient myeloma cells. As can be seen in Figure 6 , CCR2 mRNA expression was evident in the cell lines (panel a) as well as in fresh patient cells (panel b). By contrast, whereas CCR11 expression was present in the cell lines (Figure 7 ), we were unable to amplify CCR11 mRNA in fresh patient cells (data not shown). To determine whether myeloma cells expressed cell surface CCR2, we next used flow cytometry to canvass receptor expression. However, as shown in Figure 8 , each of the four cell lines tested expressed only trace levels of CCR2.
Because the data presented above suggested that myeloma cells could be induced to express MCP-1 and express receptors for this chemokine, albeit at very low levels, we next wished to determine whether MCP-1 could stimulate the myeloma cells themselves. Chemokines are known to stimulate activation of the MAPK signaling pathway. We therefore stimulated theANBL-6 and KAS-6/1 cells with MCP-1 for varying lengths of time before analyzing the activation status of
Figure 7
Myeloma cell lines express mRNA for CCR11. RT-PCR was used to assess expression of CCR11 mRNA.
Figure 8
Cell surface CCR2 expression levels. Flow cytometry was used to detect CCR2 levels using an antibody to the CKR2b isoform of CCR2.
MAPK using an antibody specific for the phosphorylated, active forms of ERKs 1 and 2. As can be seen in Figure 9 , MCP-1 stimulation resulted in the robust activation of MAPK in both cell lines. It is interesting to note the differences in kinetics of MAPK activation between the two cell lines. In contrast, MCP-1 had no effect on DNA synthesis of these two cell lines (results not shown).
Finally, because of the important role that chemokines play in cell migration, we next wished to determine if MCP-1 could stimulate myeloma cell chemotaxis. Using a standard transwell assay (Figure 10) , however, MCP-1 stimulated only modest levels of chemotaxis.
Discussion
In this paper, we report for the first time the ability of myeloma cells to express MCP-1 thereby adding a new dimension to our limited understanding of the role of chemokines in multiple myeloma. Our results also indicated that MCP-1 is MCP-1 stimulates activation of MAPK. ANBL-6 and KAS-6/1 cells were stimulated with 100 ng/ml MCP-1 for the indicated lengths of time prior to preparing total cell lysates and assessing the tyrosine phosphorylation status of ERK-1 and -2.
Figure 10
Analysis of MCP-1 stimulated myeloma cell chemotaxis. KAS-6/1 (two separate experiments shown) or KP-6 cells were tested for their ability to migrate in response to the indicated concentrations of MCP-1.
induced by IL-6. The IL-6 inducibility of this chemokine in myeloma cells is consistent with reports that IL-6 induces MCP-1 expression in other cell types including vascular smooth muscle cells 15 and peripheral blood mononuclear cells. 16 MCP-1 has been shown to be overexpressed in a variety of inflammatory diseases and tumors including atherosclerosis, rheumatoid arthritis, melanoma and breast carcinoma. 5 Although we did not examine the ability of normal plasma cells to express MCP-1 in this study, our limited analysis of plasma cells from MGUS, WM and SMM patients suggests that they will not express this chemokine. Efforts are currently underway to answer this question.
Our study also demonstrates that myeloma cells express receptors for this chemokine. Thus, our evidence for receptor expression includes the presence of mRNA for two chemokine receptors, CCR2 and CCR11; low level expression of the CCR2 isoform, CKR2b, as revealed by FACS; the ability of MCP-1 to stimulate MAPK activation in the ANBL-6 and KAS-6/1 MM cell lines; and the low level migration induced by MCP-1. Our observations that myeloma cells express CCR2 are consistent with recent results obtained by De Vos et al. 17 Thus, using expression arrays, these investigators were able to demonstrate that CCR2 was one of several genes expressed at a higher level in myeloma cell lines than in lymphoblastoid cell lines. Normal B cells have been shown by Frade et al 18 to express CCR2. In contrast, CCR11 has been shown to be virtually undetectable in peripheral blood but instead was found to be primarily expressed in the heart, small intestine and lung. 7 Our study is therefore the first demonstration of CCR11 expression in B lineage cells, although it is important to acknowledge that we failed to detect CCR11 mRNA in four MM patient samples (results not shown). Finally, it is important to note, however, that although MCP-1 receptors are clearly expressed by myeloma cells, the precise downstream consequences of MCP-1 stimulation remain to be identified. Thus, although MCP-1 stimulation resulted in robust MAPK activation, MCP-1 had no effect on cell growth (results not shown) and its effects on cell migration were modest at best. Given that other chemokines can bind to CCR2 19 and CCR11
7 such as MCP-1, 3 and 4, it remains possible that these chemokines may instead stimulate myeloma cell proliferation or more efficient chemotaxis.
The results from this study also suggest a new mechanism by which IL-6 may further impact disease pathology. In this regard, MCP-1 has been reported to play a significant role at sites of bone injury and bone remodeling as a result of MCP-1-stimulated recruitment of monocytes and subsequent elaboration of osteoclast-stimulating factors. 10 It has further been shown that MCP-1 is typically not expressed in normal bone but rather expression is induced by a number of inflammatory conditions. 11 Our data demonstrating IL-6 induction of myeloma cell MCP-1 expression suggest an additional mechanism by which the balance between bone formation and bone resorption may be disrupted in myeloma patients with lytic bone disease. In preliminary studies designed to determine whether tumor cell MCP-1 expression results in an increased migration of monocytes into the bone marrow environment, we measured the levels of CD68 and ␣-napthyl esterase-positive cells in marrow sections from myeloma and non-myeloma patients. However, despite the presence of these cells throughout the sections, we did not note a significant increase in numbers of monocytes in myelomatous marrow (results not shown). Because MCP-1 is also chemoattractant for activated and memory T cells, 20 it remains possible that myelomatous marrow contains skewed numbers of T cells as a result of tumor cell MCP-1 expression.
In addition to a high incidence of bone disease in myeloma patients, recent investigations have shown that angiogenesis is also increased in this disease and that the degree of angiogenesis parallels progression of disease. 2 Other studies have demonstrated the significance of MCP-1 and angiogenesis in breast cancer 21, 22 and recent data suggest that MCP-1 can directly mediate angiogenesis as a consequence of endothelial cell expression of the CCR2 MCP-1 receptor. 9 Our data support the hypothesis that IL-6-induced MCP-1 expression by myeloma cells may also impact angiogenesis. Finally, our exploratory studies of fresh patient tumor cells support our suggestion that MCP-1 may play a role in disease pathogenesis. However, definitive elucidation of the role of tumor cellderived MCP-1 and other chemokines in myeloma clearly requires further investigation.
